Bone Biologics (BBLG) Debt to Equity (2016 - 2017)
Historic Debt to Equity for Bone Biologics (BBLG) over the last 2 years, with Q3 2017 value amounting to -$1.97.
- Bone Biologics' Debt to Equity rose 813.76% to -$1.97 in Q3 2017 from the same period last year, while for Sep 2017 it was -$1.97, marking a year-over-year increase of 813.76%. This contributed to the annual value of -$1.05 for FY2016, which is N/A changed from last year.
- Per Bone Biologics' latest filing, its Debt to Equity stood at -$1.97 for Q3 2017, which was up 813.76% from -$1.97 recorded in Q2 2017.
- In the past 5 years, Bone Biologics' Debt to Equity registered a high of -$1.05 during Q4 2016, and its lowest value of -$2.4 during Q1 2017.